论文部分内容阅读
目的 :研究基因芯片技术检测 HBV DNA及拉米夫定耐药株在临床应用中的特异性、实用性。方法 :利用基因芯片法、双脱氧测序法分别对 4 3例服用拉米夫定且 HBV DNA仍为阳性的乙型肝炎 (乙肝 )患者及 10例非乙肝患者的血清进行 HBV DNA和 P区 5 2 8、5 5 2、5 5 5突变位点检测、对比。结果 :两种方法检测 HBV DNA10 0 %相符 ;检测拉米夫定耐药突变株 12 4个位点结果相符 ,5个位点结果不相符 (P >0 .0 5 ) ,提示两种方法检测HBV DNA及 P区 5 2 8、5 5 2、5 5 5突变位点阳性率相等。结论 :利用基因芯片技术检测 HBV DNA及拉米夫定耐药株 ,其特异性可与 DNA测序媲美 ,在混合株检测方面比 DNA测序有更大的优势。其方法简便 ,能大量地对临床标本进行检测 ,可作为临床常规检测手段。
Objective: To study the specificity and practicability of gene chip technique for detecting HBV DNA and lamivudine resistant strains in clinical application. Methods: HBV DNA and P region 5 were detected in sera of 43 hepatitis B patients (hepatitis B patients) and 10 non-hepatitis B patients who were treated with lamivudine and HBV DNA still positive by gene chip method and dideoxy sequencing. 2 8,5 5 2,5 5 5 Mutation site detection, comparison. Results: The results of two methods were consistent with 100% HBV DNA. The results of 12 tested loci of lamivudine-resistant mutants were consistent and the results of 5 loci did not match (P> 0.05) HBV DNA and P region 5 2 8,5 5 2,5 5 5 mutation sites the same positive rate. Conclusion: The detection of HBV DNA and lamivudine-resistant strains using gene chip technology is comparable to DNA sequencing and has greater advantages than DNA sequencing in the detection of mixed strains. The method is simple, can be a large number of clinical specimens for testing, can be used as a routine clinical test.